骨优势转移性乳腺癌内分泌治疗反应预测:FDG与NaF PET/CT及全身MRI扩散加权成像的比较
本研究比较FDG与NaF PET/CT及全身MRI扩散加权成像(WB-MRI)在骨优势转移性乳腺癌内分泌治疗8周时预测治疗反应的价值。结果显示FDG PET/CT和WB-MRI最能预测临床非进展,FDG和NaF PET/CT均能预测PFS<24周,且各模态均存在病灶间反应异质性,NaF闪烁现象常见。
要点
- FDG PET/CT和WB-MRI对临床非进展的预测特异性均为100%,但敏感性均为0%。
- NaF PET/CT预测24周临床进展的敏感性60%、特异性73.3%、准确性70%。
- FDG和NaF PET/CT的SUVmax变化与PFS<24周相关,ADCmed变化不相关。
核心结论
- FDG PET/CT和WB-MRI最能预测临床非进展,FDG和NaF PET/CT均能预测PFS<24周。
- 各模态均存在病灶间反应异质性,NaF PET/CT闪烁现象常见。
研究设计与样本
- 基线及8周行FDG和NaF PET/CT(测SUVmax)及WB-MRI(测ADCmed),若8周SUVmax升高则12周加做NaF PET/CT以检测闪烁现象。
- 以25%参数变化区分影像学进展与非进展,与24周临床参考标准及PFS比较。
主要发现
- NaF SUVmax变化预测24周临床进展的敏感性、特异性和准确性分别为60%、73.3%和70%。
- FDG SUVmax变化预测24周临床进展的敏感性、特异性和准确性分别为0、100%和76.2%。
- ADCmed变化预测24周临床进展的敏感性、特异性和准确性分别为0、100%和72.2%。
- PFS<24周与NaF SUVmax变化(41.7% vs. 0.7%,p=0.039)和FDG SUVmax变化(-4.8% vs. -28.6%,p=0.005)相关,与ADCmed变化无关(-0.5% vs. 10.1%,p=0.098)。
- 所有模态均出现病灶间反应异质性,7例患者出现NaF闪烁现象。
关键数值与推荐
- 以25%参数变化作为区分影像学进展与非进展的阈值。
- 临床参考标准为24周临床进展评估,PFS以24周为界。
临床怎么用
- FDG PET/CT和WB-MRI可用于排除骨优势转移性乳腺癌内分泌治疗后的临床进展,但阴性结果不能排除进展。
- NaF PET/CT可辅助预测内分泌治疗进展风险,但需注意闪烁现象和病灶间异质性对判读的影响。
局限性
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare [18F]-fluorodeoxyglucose (FDG) and [18F]-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endocrine therapy response prediction at 8 weeks in bone-predominant metastatic breast cancer. PATIENTS AND METHODS: Thirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF PET/CT: maximum standardized uptake value (SUVmax); WB-MRI: median apparent diffusion coefficient (ADCmed)] at baseline and 8 weeks. To detect the flare phenomenon, a 12-week NaF PET/CT was also performed if 8-week SUVmax increased. A 25% parameter change differentiated imaging progressive disease (PD) from non-PD and was compared to a 24-week clinical reference standard and progression-free survival (PFS). RESULTS: Twenty-two patients (median age, 58.6 years, range, 40-79 years) completing baseline and 8-week imaging were included in the final analysis. Per-patient % change in NaF SUVmax predicted 24-week clinical PD with sensitivity, specificity and accuracy of 60, 73.3, and 70%, respectively. For FDG SUVmax the results were 0, 100, and 76.2% and for ADCmed, 0, 100 and 72.2%, respectively. PFS < 24 weeks was associated with % change in SUVmax (NaF: 41.7 vs. 0.7%, p = 0.039; FDG: - 4.8 vs. - 28.6%, p = 0.005) but not ADCmed (- 0.5 vs. 10.1%, p = 0.098). Interlesional response heterogeneity occurred in all modalities and NaF flare occurred in seven patients. CONCLUSIONS: FDG PET/CT and WB-MRI best predicted clinical non-PD and both FDG and NaF PET/CT predicted PFS < 24 weeks. Lesional response heterogeneity occurs with all modalities and flare is common with NaF PET/CT.
引用
- Azad GK, Taylor BP, Green A, et al. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. Eur J Nucl Med Mol Imaging. 2018. PMID: 30506455. doi:10.1007/s00259-018-4223-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。